MedTrace Logo

Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects

NCT03466736 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 165

Last updated 2023-04-28

No results posted yet for this study

Summary

The primary objective of this study is to demonstrate that individuals with low short-term practice effects (STPE) on cognitive testing are more likely to be identified as "positive" on amyloid imaging than individuals with high STPE. STPE may also inform us about other AD-related biomarkers, including hippocampal volumes, functional connectivity, and APOE status. By realizing the aims of this pragmatic study, we hope to be able to offer more economical and efficient screening of potential participants for clinical trials, which would reduce participant burden and financial costs.

Conditions

Interventions

DIAGNOSTIC_TEST

[18F]flutemetamol PET scan

Each subject will receive an amyloid PET scan with \[18F\]flutemetamol

Sponsors & Collaborators

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2023-04-20
Completion
2023-04-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03466736 on ClinicalTrials.gov